These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 17052145)

  • 1. Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy.
    Teng MW; Kershaw MH; Jackson JT; Smyth MJ; Darcy PK
    Hum Gene Ther; 2006 Nov; 17(11):1134-43. PubMed ID: 17052145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
    Ma Q; Gomes EM; Lo AS; Junghans RP
    Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
    Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
    Altenschmidt U; Klundt E; Groner B
    J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
    Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
    Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
    Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ; Darcy PK
    J Immunol; 2001 Jan; 166(1):182-7. PubMed ID: 11123291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
    Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
    Front Immunol; 2018; 9():2231. PubMed ID: 30364107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor ablation by gene-modified T cells in the absence of autoimmunity.
    Wang LX; Westwood JA; Moeller M; Duong CP; Wei WZ; Malaterre J; Trapani JA; Neeson P; Smyth MJ; Kershaw MH; Darcy PK
    Cancer Res; 2010 Dec; 70(23):9591-8. PubMed ID: 21098715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
    Arakawa F; Shibaguchi H; Xu Z; Kuroki M
    Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.
    Wang J; Jensen M; Lin Y; Sui X; Chen E; Lindgren CG; Till B; Raubitschek A; Forman SJ; Qian X; James S; Greenberg P; Riddell S; Press OW
    Hum Gene Ther; 2007 Aug; 18(8):712-25. PubMed ID: 17685852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors.
    Ren-Heidenreich L; Hayman GT; Trevor KT
    Hum Gene Ther; 2000 Jan; 11(1):9-19. PubMed ID: 10646635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
    Lo AS; Ma Q; Liu DL; Junghans RP
    Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.
    Loskog A; Giandomenico V; Rossig C; Pule M; Dotti G; Brenner MK
    Leukemia; 2006 Oct; 20(10):1819-28. PubMed ID: 16932339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy.
    Cheung NK; Guo HF; Modak S; Cheung IY
    Hybrid Hybridomics; 2003 Aug; 22(4):209-18. PubMed ID: 14511566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing Fcepsilon-Bak chimeric protein for studying IgE-FcepsilonRI interactions.
    Belostotsky R; Lorberboum-Galski H
    Clin Immunol; 2004 Jan; 110(1):89-99. PubMed ID: 14962800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
    Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
    Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.
    Roberts MR; Cooke KS; Tran AC; Smith KA; Lin WY; Wang M; Dull TJ; Farson D; Zsebo KM; Finer MH
    J Immunol; 1998 Jul; 161(1):375-84. PubMed ID: 9647246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
    Teng MW; Kershaw MH; Moeller M; Smyth MJ; Darcy PK
    Hum Gene Ther; 2004 Jul; 15(7):699-708. PubMed ID: 15242530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.